47 results on '"Kauffmann-Guerrero, Diego"'
Search Results
2. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
3. Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire
4. Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.
5. The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [ 18 F]FDG-PET/CT of Patients with Lung Cancer.
6. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
7. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
8. Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testing.
9. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients
10. Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality
11. sj-pdf-1-tar-10.1177_17534666221148663 – Supplemental material for Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality
12. sj-docx-2-tar-10.1177_17534666221148663 – Supplemental material for Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality
13. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort
14. Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET
15. Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC
16. Additional file 2 of Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire
17. sj-docx-1-onc-10.1177_11795549221123618 – Supplemental material for Changes in Behavior After Vaccination and Opinions Toward Mask Wearing: Thoracic Oncology Patient–Reported Experiences During the COVID-19 Pandemic
18. Additional file 1 of Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire
19. Lymphocytes and sinus histiocytosis in tumor and matched lymph nodes as predictors of survival in non-small-cell lung cancer
20. Changes in Behavior After Vaccination and Opinions Toward Mask Wearing: Thoracic Oncology Patient–Reported Experiences During the COVID-19 Pandemic
21. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
22. Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
23. Additional file 1 of Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
24. New developments in locally advanced nonsmall cell lung cancer
25. Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences
26. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
27. Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
28. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
29. Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
30. Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
31. Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
32. Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells
33. Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies
34. Late-onset severe pneumonitis under osimertinib
35. Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy
36. Simultaneous Occurrence of HER2Mutations in EGFRMutant NSCLC: Case Reports
37. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
38. Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography
39. Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer
40. P1.06-035 Frequency and Clinical Relevance of EGFR-Mutations and EML4-ALK-Translocations in Octagenarians with NSCLC
41. Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.
42. Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.
43. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort.
44. Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2mutations
45. Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.
46. Clinicopathological characterization of next-generation sequencing detected mutations in lung cancers-a single-center experience.
47. Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.